08:55 EDT AbbVie (ABBV) jumps 4% to $220.77 after settling with Rinvoq generic makers
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie Settles to Delay RINVOQ Generics Until 2037
- AstraZeneca and AbbVie: New Phase II Study Targets Relapsed CLL/SLL
- AbbVie’s ABBV-525 Study: A Potential Game-Changer in B-Cell Malignancies
- AbbVie’s Promising Phase 2 Study on ABBV-932 for Anxiety Disorder
- AbbVie’s Promising Study on ABBV-706 for Small Cell Lung Cancer